Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
sarepta therapeutics將會上漲約30%?以下是週四的10位頂尖分析師預測
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
華爾街頂級分析師改變了對這些知名人士的看法。要全面了解所有分析師評級變動,包括上調和降級,請參閱我們的分析師評級頁面。
- Piper Sandler boosted Duolingo, Inc. (NASDAQ:DUOL) price target from $271 to $351. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Duolingo shares closed at $318.85 on Wednesday. See how other analysts view this stock.
- B of A Securities cut the price target for Bloom Energy Corporation (NYSE:BE) from $8 to $7. B of A Securities analyst Julien Dumoulin-Smith maintained an Underperform rating. Bloom Energy shares closed at $10.97 on Wednesday. See how other analysts view this stock.
- Needham raised the price target for Vertex, Inc. (NASDAQ:VERX) from $45 to $60. Needham analyst Joshua Reilly maintained a Buy rating. Vertex shares closed at $49.76 on Wednesday. See how other analysts view this stock.
- Baird increased McKesson Corporation (NYSE:MCK) price target from $531 to $688. Baird analyst Eric Coldwell upgraded the stock from Neutral to Outperform. McKesson shares settled at $549.31 on Wednesday. See how other analysts view this stock.
- TD Cowen raised Dutch Bros Inc. (NYSE:BROS) price target from $47 to $53. TD Cowen analyst Andrew Charles maintained a Buy rating. Dutch Bros shares closed at $34.94 on Wednesday. See how other analysts view this stock.
- Truist Securities cut Devon Energy Corporation (NYSE:DVN) price target from $49 to $43. Truist Securities analyst Neal Dingmann downgraded the stock from Buy to Hold. Devon Energy shares closed at $40.02 on Wednesday. See how other analysts view this stock.
- Cantor Fitzgerald raised the price target for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) from $152 to $167. Cantor Fitzgerald analyst Kristen Kluska upgradd the stock from Neutral to Overweight. Sarepta shares settled at $127.97 on Wednesday. See how other analysts view this stock.
- Leerink Partners raised Zymeworks Inc. (NASDAQ:ZYME) price target from $10 to $25. Leerink Partners analyst Andrew Berens upgraded the stock from Market Perform to Outperform. Zymeworks shares closed at $15.61 on Wednesday. See how other analysts view this stock.
- Loop Capital slashed the price target for Crocs, Inc. (NYSE:CROX) from $150 to $110. Loop Capital analyst Laura Champine downgraded the stock from Buy to Hold. Crocs shares closed at $102.74 on Wednesday. See how other analysts view this stock.
- Keefe, Bruyette & Woods increased Lemonade, Inc. (NYSE:LMND) price target from $18 to $21. Keefe, Bruyette & Woods analyst Thomas McJoynt-Griffith downgraded the stock from Market Perform to Underperform. Lemonade shares closed at $29.29 on Wednesday. See how other analysts view this stock.
- 派珀·桑德勒將Duolingo, Inc.(納斯達克股票代碼:DUOL)的目標股價從271美元上調至351美元。派珀·桑德勒分析師阿文德·拉姆納尼維持增持評級。週三,Duolingo股價收於318.85美元。看看其他分析師如何看待這隻股票。
- b的A證券將布盧姆能源公司(紐約證券交易所代碼:BE)的目標股價從8美元下調至7美元。b的A證券分析師朱利恩·杜穆林-史密斯維持了表現不佳的評級。布魯姆能源股價週三收於10.97美元。看看其他分析師如何看待這隻股票。
- 尼德姆將Vertex, Inc.(納斯達克股票代碼:VERX)的目標股價從45美元上調至60美元。尼德姆分析師約書亞·賴利維持買入評級。Vertex股價週三收於49.76美元。看看其他分析師如何看待這隻股票。
- 貝爾德將麥克森公司(紐約證券交易所代碼:MCK)的目標股價從531美元上調至688美元。貝爾德分析師埃裏克·科德威爾將該股從中性上調至跑贏大盤。麥克森股價週三收於549.31美元。看看其他分析師如何看待這隻股票。
- 道明考恩將荷蘭兄弟公司(紐約證券交易所代碼:BROS)的目標股價從47美元上調至53美元。道明考恩分析師安德魯查爾斯維持買入評級。荷蘭兄弟股價週三收於34.94美元。看看其他分析師如何看待這隻股票。
- Truist Securities將德文能源公司(紐約證券交易所代碼:DVN)的目標股價從49美元下調至43美元。Truist Securities分析師尼爾·丁曼將該股的評級從買入下調至持有。德文能源股價週三收於40.02美元。看看其他分析師如何看待這隻股票。
- 坎託·菲茨傑拉德將薩雷普塔療法公司(納斯達克股票代碼:SRPT)的目標股價從152美元上調至167美元。坎託·菲茨傑拉德分析師克里斯汀·克魯斯卡將該股從中性上調至增持。週三,薩雷普塔股價收於127.97美元。看看其他分析師如何看待這隻股票。
- Leerink Partners將Zymeworks Inc.(納斯達克股票代碼:ZYME)的目標股價從10美元上調至25美元。Leerink Partners分析師安德魯·貝倫斯將該股從市場表現上調至跑贏大盤。Zymeworks股價週三收於15.61美元。看看其他分析師如何看待這隻股票。
- Loop Capital將Crocs, Inc.(紐約證券交易所代碼:CROX)的目標股價從150美元下調至110美元。Loop Capital分析師勞拉·尚平將該股的評級從買入下調至持有。Crocs股價週三收於102.74美元。看看其他分析師如何看待這隻股票。
- Keefe、Bruyette & Woods將Lemonade, Inc.(紐約證券交易所代碼:LMND)的目標股價從18美元上調至21美元。Keefe、Bruyette & Woods分析師托馬斯·麥喬因-格里菲斯將該股的評級從市場表現下調至表現不佳。Lemonade股價週三收於29.29美元。看看其他分析師如何看待這隻股票。
Read More:
閱讀更多:
- Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom
- 吉姆·克萊默:像博通一樣,這隻金融股值得買入